Deutsche Bank AG Makes New $3.80 Million Investment in Immunovant, Inc. $IMVT

Posted by George Bondi on Aug 26th, 2026

Deutsche Bank AG bought a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the second quarter, Holdings Channel.com reports. The firm bought 98,595 shares of the company’s stock, valued at approximately $3,799,000.

A number of other hedge funds also recently made changes to their positions in the stock. Geneos Wealth Management Inc. bought a new stake in shares of Immunovant during the 4th quarter valued at approximately $25,000. Strs Ohio bought a new position in Immunovant in the 1st quarter valued at approximately $27,000. PNC Financial Services Group Inc. boosted its position in Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock valued at $46,000 after buying an additional 1,646 shares in the last quarter. Quarry LP grew its stake in shares of Immunovant by 94.9% during the fourth quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $76,000 after buying an additional 1,461 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Immunovant by 228.9% during the second quarter. Tower Research Capital LLC TRC now owns 6,140 shares of the company’s stock worth $98,000 after buying an additional 4,273 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors and hedge funds.

Immunovant Price Performance

IMVT opened at $43.50 on Wednesday. Immunovant, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $45.42. The firm has a market capitalization of $8.98 billion, a price-to-earnings ratio of -15.43 and a beta of 0.77. The company’s 50 day moving average price is $39.82 and its two-hundred day moving average price is $32.04.

Immunovant (NASDAQ:IMVT – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The firm had revenue of $7.09 million for the quarter, compared to analysts’ expectations of $7.09 million. During the same period in the prior year, the firm earned ($0.71) earnings per share. As a group, equities research analysts predict that Immunovant, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Citigroup upped their price target on shares of Immunovant from $57.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Truist Financial raised their price objective on Immunovant from $23.00 to $30.00 and gave the company a “hold” rating in a report on Friday, May 22nd. JPMorgan Chase & Co. boosted their price objective on Immunovant from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Sanford C. Bernstein raised Immunovant to a “hold” rating in a report on Wednesday, July 29th. Finally, Bank of America increased their target price on Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

View Our Latest Stock Report on Immunovant

Insider Buying and Selling

In other Immunovant news, Director Atul Pande sold 1,500 shares of Immunovant stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $38.01, for a total transaction of $57,015.00. Following the transaction, the director directly owned 116,731 shares of the company’s stock, valued at approximately $4,436,945.31. The trade was a 1.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 3,092 shares of Immunovant stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $38.48, for a total value of $118,980.16. Following the transaction, the chief executive officer directly owned 254,280 shares in the company, valued at $9,784,694.40. The trade was a 1.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 318,810 shares of company stock valued at $11,158,166 over the last quarter. 1.90% of the stock is currently owned by company insiders.

Immunovant Profile

(Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.